Alnylam raises FY25 revenue view to $2.65B-$2.8B from $2.05B-$2.25B

Consensus $3.02B. Greenstreet continued, “We also continue to advance key programs in our robust pipeline, with the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM underway, and two more Phase 3 trials on track to start this year: TRITON-PN for nucresiran in hATTR-PN and the cardiovascular outcomes trial of zilebesiran in hypertension. The remarkable pace and depth of our progress positions us to deliver on our Alnylam (ALNY) P5x25 goals as we advance toward sustainable profitability and solidify ourselves as a top-tier biotech company delivering transformational innovation to patients.”